Suppr超能文献

抗抑郁药对患有重度抑郁症青少年的比较疗效:台湾一项基于全国人口的研究。

The comparative effectiveness of antidepressants for youths with major depressive disorder: a nationwide population-based study in Taiwan.

作者信息

Lee Sheng-Yu, Wang Liang-Jen, Yang Yao-Hsu, Hsu Chih-Wei

机构信息

Department of Psychiatry, Kaohsiung Veterans General Hospital, Kaohsiung.

Department of Child and Adolescent Psychiatry, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung.

出版信息

Ther Adv Chronic Dis. 2022 May 22;13:20406223221098114. doi: 10.1177/20406223221098114. eCollection 2022.

Abstract

BACKGROUND

Guidelines recommend fluoxetine as a first-line medication for youths diagnosed with major depressive disorder (MDD). However, little is known about the long-term effectiveness of different antidepressants in juveniles in the real world. This study aimed to compare the effectiveness of antidepressants in youths with MDD.

METHODS

Youths (<20 years old) with a diagnosis of MDD who were new users of antidepressants were selected from a nationwide population-based cohort in Taiwan between 1997 and 2013. We divided a total of 16,981 users (39.9% male; mean age: 16.6 years) into 10 different antidepressant groups (fluoxetine, sertraline, paroxetine, venlafaxine, citalopram, escitalopram, bupropion, fluvoxamine, mirtazapine and moclobemide). Regarding treatment outcomes (hospitalisation and medication discontinuation), Cox proportional hazards regression models were applied to estimate the hazards of such outcomes.

RESULTS

Compared with the youths treated with fluoxetine, the bupropion-treated group demonstrated lower rates of hospitalisation and discontinuation. Mirtazapine-treated group demonstrated a higher hospitalisation risk mainly when administered for single depressive episodes. Furthermore, patients treated with sertraline and fluvoxamine had higher discontinuation rates. Among the younger teenage subgroups (< 16 years), significantly higher rates of discontinuation were observed in those treated with sertraline, escitalopram and fluvoxamine. Among the older teenage subgroups (⩾ 16 years), bupropion was superior to fluoxetine in preventing hospitalisation and discontinuation.

CONCLUSION

We concluded that bupropion might surpass fluoxetine with regard to hospitalisation prevention and drug therapy maintenance among youths with MDD, while mirtazapine users demonstrated a higher hospitalisation risk. Our findings might serve as a reference for clinicians in future studies.

摘要

背景

指南推荐氟西汀作为诊断为重度抑郁症(MDD)的青少年的一线用药。然而,在现实世界中,对于不同抗抑郁药在青少年中的长期疗效知之甚少。本研究旨在比较抗抑郁药对患有MDD的青少年的疗效。

方法

选取1997年至2013年台湾全国性基于人群的队列中诊断为MDD且新使用抗抑郁药的青少年(<20岁)。我们将总共16981名使用者(39.9%为男性;平均年龄:16.6岁)分为10个不同的抗抑郁药组(氟西汀、舍曲林、帕罗西汀、文拉法辛、西酞普兰、艾司西酞普兰、安非他酮、氟伏沙明、米氮平和吗氯贝胺)。关于治疗结果(住院和停药),应用Cox比例风险回归模型来估计此类结果的风险。

结果

与接受氟西汀治疗的青少年相比,接受安非他酮治疗的组住院率和停药率较低。米氮平治疗组主要在用于单次抑郁发作时显示出较高的住院风险。此外,接受舍曲林和氟伏沙明治疗的患者停药率较高。在较年轻的青少年亚组(<16岁)中,接受舍曲林、艾司西酞普兰和氟伏沙明治疗的患者停药率明显更高。在较年长的青少年亚组(≥16岁)中,安非他酮在预防住院和停药方面优于氟西汀。

结论

我们得出结论,在预防住院和维持药物治疗方面,安非他酮在患有MDD的青少年中可能优于氟西汀,而使用米氮平的患者显示出较高的住院风险。我们的研究结果可能为临床医生未来的研究提供参考。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b62/9131383/e96e47caf01e/10.1177_20406223221098114-fig1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验